CD19 and B-cell chronic lymphocytic leukemia: The use of CD19 as a target in the case of CLL by producing anti-CD19 CAR-T cells has shown remarkable results in patients with complete remission and minimal residual disease, and anti-CD19-CD28ζ CAR-T cells have shown promising results, according to the data from the National Cancer Institute (Porter et al., 2011, 2015; Kochenderfer et al., 2015).